A Phase 2 interventional study of LTP001 in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 12 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 6th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 2, and was the 11th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 40 across 477 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to measure the long-term safety and efficacy profile of LTP001 in participants with pulmonary arterial hypertension (PAH). The study offered participants who had completed the CLTP001A12201 double-blind parent study in PAH an opportunity to receive LTP001 (whether they were on LTP001 or not). Unblinding of the treatment received in CLTP001A12201 was generally not needed but could occur on request by the investigator.
This was a non-randomized, open-label extension study of LTP001 for participants with PAH who completed the parent Study CLTP001A12201. Eligible participants were presented with the opportunity to enroll in the extension study at the end of treatment visit of the parent study. Participants in the extension study were planned to receive a once-daily dose of LTP001 for 52 weeks regardless of their parent study treatment (i.e. LTP001 or placebo). The study duration was planned up to 54 weeks with a treatment duration up to 52 weeks and maximum 2-week transition period from the CLTP001A12201 study. The visit frequency was planned to include visits at Weeks 1, 5, 13, 26, 39, 52, and 54 along with optional visits at the discretion of the Investigators at Weeks 9 and 17.
Due to the study termination, no patient reached Week 52. After the termination announcement, following the instruction to immediately stop treatment for all participants, an end-of-treatment (EOT) visit was conducted. Sites were advised to complete protocol-required assessments based on investigator judgement and patient willingness to undergo procedures, with a primary focus on ensuring a safe exit from the study. Most sites performed only a few safety assessments, and only a minimal number of patients completed an echocardiogram.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
Women were considered if they had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms). Women were considered not of child-bearing potential if they were post-menopausal or had surgical bilateral oophorectomy (with or without hysterectomy) or total hysterectomy at least six weeks prior. In the case of oophorectomy alone, only when the reproductive status of the woman had been confirmed by follow up hormone level assessment was she considered not of child bearing potential.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LTP001, 6 mg, orally once daily in the morning for approximately 39 weeks
Drug: LTP001
LTP001, 6 mg, was administered orally once daily in the morning
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Incidence and severity of adverse events (AEs) by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs. Due to the study termination, no patient reached Week 52. At the end of treatment visit, final safety assessments were performed.
Time frame: Up to approximately 45 weeks
Change From Baseline in Average Cardiac Output (CO) at Week 26
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including CO.
Time frame: Baseline, Week 26
Change From Baseline in Mean Pulmonary Artery (PA) Pressure at Week 26
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including PA pressure.
Time frame: Baseline, Week 26
Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 26
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).
Time frame: Baseline, Week 26
Change From Baseline in Right Heart Catheterization Pulmonary Vascular Resistance (PVR) at Week 26
PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dynes.sec.cm-5.
Time frame: Baseline, Week 26
Change From Baseline in Right Atrium (RA) Pressures at Week 26
The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.
Time frame: Baseline, Week 26
Change From Baseline in Systemic Vascular Resistance (SVR) at Week 26
The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including SVR.
Time frame: Baseline, Week 26
Change From Baseline in Six Minute Walk Distance (6MWD)
6MWD test measures the distance that a participant can walk on a flat, hard surface in a period of 6 minutes. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
Time frame: Baseline, Week 26, up to 39 weeks (EOT)
Change From Baseline in Tricuspid Annular Plane Systolic Excursion (TAPSE)
Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
Time frame: Baseline, Week 26, up to 39 weeks (EOT)
Change From Baseline in Tricuspid Annular Plane Systolic Velocity (TASV)
Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
Time frame: Baseline, Week 26, up to 39 weeks (EOT)
Change From Baseline in Peak Velocity of Excursion (RV S')
Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
Time frame: Baseline, Week 26, up to 39 weeks (EOT)
Change From Baseline in Fractional Area Change (FAC)
Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
Time frame: Baseline, Week 26, up to 39 weeks (EOT)
Change From Baseline in Quality of Life Measured by the emPHasis-10 Questionnaire
emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
Time frame: Baseline up to 39 weeks (EOT)
Change From Baseline in Quality of Life Measured by the PAH-SYMPACT Questionnaire
PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
Time frame: Baseline up to 39 weeks (EOT)
Time to Clinical Worsening
Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six-minute walk distance Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
Time frame: Baseline up to 39 weeks (EOT)
Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP)
NT-proBNP is a blood biomarker to assess right ventricular distress. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
Time frame: Baseline up to 39 weeks (EOT)
| Milestone | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Started | 23 | 8 |
| Completed | 0 | 0 |
| Not completed | 23 | 8 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 1 | 8 |
| Withdrew: Study terminated by sponsor | 20 | 0 |
| Withdrew: Participant decision | 1 | 0 |
Incidence and severity of adverse events (AEs) by treatment group, including changes in the vital signs, electrocardiogram and laboratory results qualifying and reported as AEs. Due to the study termination, no patient reached Week 52. At the end of treatment visit, final safety assessments were performed.
| Percentage of participants | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| AEs | 52.2 | 62.5 |
| Serious AEs | 17.4 | 0 |
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including CO.
| liters per minute | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Average Cardiac Output (CO) at Week 26 | -0.111 ± 0.2153 | -0.065 ± 0.5916 |
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including PA pressure.
| mmHg | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Mean Pulmonary Artery (PA) Pressure at Week 26 | 3.8 ± 8.18 | -1.5 ± 7.78 |
Right heart catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including pulmonary capillary wedge pressure (PCWP).
| mmHg | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Pulmonary Capillary Wedge Pressure (PCWP) at Week 26 | -1.0 ± 1.79 | -0.5 ± 0.71 |
PVR was defined as the resistance against blood flow from the pulmonary artery to the left atrium measured in dynes.sec.cm-5.
| dynes.sec.cm-5 | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Right Heart Catheterization Pulmonary Vascular Resistance (PVR) at Week 26 | 100.058 ± 95.5879 | -7.445 ± 34.8250 |
The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including RA pressures.
| mmHg | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Right Atrium (RA) Pressures at Week 26 | -1.5 ± 6.22 | 0.0 ± 2.83 |
The Right Heart Catheterization (RHC) assessment was performed to assess several hemodynamic variables in pulmonary hypertension, including SVR.
| dynes.sec.cm-5 | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Systemic Vascular Resistance (SVR) at Week 26 | 166.748 ± 128.6202 | -49.710 ± 28.5388 |
6MWD test measures the distance that a participant can walk on a flat, hard surface in a period of 6 minutes. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
| meters | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Week 26 n=6,2 | -33.7 ± 55.60 | -9.0 ± 25.46 |
| EOT n=16,2 | -6.3 ± 50.21 | -1.0 ± 1.41 |
Key right ventricular (RV) function endpoints such as tricuspid annular plane systolic excursion (TAPSE) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
| centimeters | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Week 26 n=6,2 | 0.03 ± 0.175 | 0.00 ± 0.283 |
| EOT n=7,0 | 0.01 ± 0.682 | — |
Key right ventricular (RV) function endpoints such as tricuspid annular systolic velocity (TASV) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
| centimeters per second | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Week 26 n=6,2 | -2.2 ± 3.43 | -0.5 ± 0.71 |
| EOT n=7,0 | -2.6 ± 1.90 | — |
Key right ventricular (RV) function per echocardiography. The terms Tricuspid Annular Systolic Velocity (TASV) and Peak Velocity of Excursion (RV S') are synonymous in echocardiography to describe the peak systolic velocity of the lateral tricuspid annulus. Including both TASV and RV S' as separate secondary endpoints was an oversight in the protocol as the data, calculation, and analyses for both (TASV and RV S') are identical. Therefore, the TASV and RV S' data in this results disclosure are the same. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
| centimeters per second | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Week 26 n=6,2 | -2.2 ± 3.43 | -0.5 ± 0.71 |
| EOT n=7,0 | -2.6 ± 1.90 | — |
Key right ventricular (RV) function endpoints such as RV fractional area change (RV FAC) were assessed with echocardiography. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures. Only a minimal number of patients completed an echocardiogram (Echo).
| percent | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Week 26 n=6,1 | -0.87 ± 6.162 | 7.30 ± NA |
| EOT n=6,0 | 0.97 ± 5.290 | — |
emPHasis-10 is a questionnaire with 10 questions designed to determine how pulmonary hypertension affects a participant's life. Each item is scored on a scale of 0 to 5, with a total score ranging from 0 to 50. A higher score indicates worse quality of life. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
| score | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Quality of Life Measured by the emPHasis-10 Questionnaire | 1.476 ± 2.3226 | 1.000 ± NA |
PAH-SYMPACT is a questionnaire used to assess pulmonary arterial hypertension symptoms and their impact. Individual item scores range from 0 to 4. Total score is calculated as the sum of the scores for the individual items divided by the number of items. A higher score indicates more severe symptoms/impacts. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
| score | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in Quality of Life Measured by the PAH-SYMPACT Questionnaire | 2.929 ± 2.3234 | -0.833 ± NA |
Time to any of the following: * Death * Hospital stay greater than 24 hours due to worsening of pulmonary arterial hypertension * Worsening of PAH resulting in need for lung transplantation or balloon atrial septostomy * Initiation of parenteral prostanoid therapy, initiation of oxygen therapy, initiation of any other pulmonary arterial hypertension-specific therapies or need for increase of diuretics for more than 4 weeks due to worsening of pulmonary arterial hypertension * Significant drop in six-minute walk distance Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
| days | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Time to Clinical Worsening | 346.0 (187.0 to NA) | — |
NT-proBNP is a blood biomarker to assess right ventricular distress. Due to the study termination, no patient reached Week 52. At the end of treatment (EOT) visit, final safety assessments were performed based on investigator judgement and patient willingness to undergo procedures.
| picomoles per liter | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) |
|---|---|---|
| Change From Baseline in N-terminal Fragment of the Prohormone B-type Natriuretic Peptide (NT-ProBNP) | 3.832 ± 31.2255 | 7.250 ± 16.6033 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 6 weeks post treatment, up to approximately 45 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LTP001 6 mg (Actual Treatment in CLTP001A12201) | 0/23 (0%) | 4/23 (17.4%) | 5/23 (21.7%) |
| LTP001 6 mg (Placebo in CLTP001A12201) | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Total | 0/31 (0%) | 4/31 (12.9%) | 10/31 (32.3%) |
| Event | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) | Total |
|---|---|---|---|
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 2/23 | 0/8 | 2/31 |
| Medical device site haemorrhageGeneral disorders and administration site conditions | 1/23 | 0/8 | 1/31 |
| Device related infectionInfections and infestations | 1/23 | 0/8 | 1/31 |
| Disseminated gonococcal infectionInfections and infestations | 1/23 | 0/8 | 1/31 |
| Event | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) | Total |
|---|---|---|---|
| LymphadenopathyBlood and lymphatic system disorders | 0/23 | 1/8 | 1/31 |
| Eczema eyelidsEye disorders | 0/23 | 1/8 | 1/31 |
| FatigueGeneral disorders and administration site conditions | 0/23 | 1/8 | 1/31 |
| BartholinitisInfections and infestations | 0/23 | 1/8 | 1/31 |
| BronchitisInfections and infestations | 0/23 | 1/8 | 1/31 |
| NasopharyngitisInfections and infestations | 2/23 | 1/8 | 3/31 |
| Tooth abscessInfections and infestations | 0/23 | 1/8 | 1/31 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/23 | 1/8 | 1/31 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/23 | 1/8 | 1/31 |
| DizzinessNervous system disorders | 0/23 | 1/8 | 1/31 |
| Age, Continuous(Years) | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) | Total |
|---|---|---|---|
| Mean | 47.0 ± 11.76 | 48.4 ± 13.35 | 47.4 ± 11.97 |
| Age, Customized(Participants) | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) | Total |
|---|---|---|---|
| 18 - <65 | 20 | 7 | 27 |
| 65 - <85 | 3 | 1 | 4 |
| Sex: Female, Male(Participants) | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) | Total |
|---|---|---|---|
| Female | 21 | 6 | 27 |
| Male | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | LTP001 6 mg (Actual Treatment in CLTP001A12201) | LTP001 6 mg (Placebo in CLTP001A12201) | Total |
|---|---|---|---|
| White | 21 | 7 | 28 |
| American Indian or Alaskan | 2 | 0 | 2 |
| Asian | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2023 to primary completion in Apr 2024, 12 months.
Results were first posted in Dec 2025, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LTP001
Pulmonary Arterial Hypertension →